Quick Summary
- Trial Result: Eli Lilly’s Taltz (ixekizumab) outperformed Janssen’s Tremfya (guselkumab) in a head-to-head Phase IV study.
- Primary Outcome: 41% of patients treated with Taltz achieved complete skin clearance by Week 12.
- Key Secondary Outcomes: Superior results in early improvements (PASI 75 at Week 2, PASI 90 at Week 4).
- Implication: Positions Taltz as a leading option for moderate-to-severe plaque psoriasis.
Eli Lilly recently announced compelling results from its Phase IV IXORA-R clinical trial, where Taltz demonstrated significant efficacy over Janssen’s Tremfya in patients with moderate-to-severe plaque psoriasis. Taltz, an IL-17A inhibitor, achieved 41% complete skin clearance (PASI 100) by Week 12, a rate nearly double that of Tremfya, an IL-23/p19 inhibitor, which showed a clearance rate of 24.9% at the same interval. The findings, shared at the Maui Derm NP+PA conference, also highlight the benefits of Taltz in achieving rapid early response, meeting several secondary endpoints, including PASI 75 at Week 2 and PASI 90 by Week 4.
Lotus Mallbris, Eli Lilly’s VP of immunology development, emphasized that these results meet the high treatment standards that patients and healthcare providers seek, especially for those aiming for rapid skin clearance and long-term disease control. With psoriasis affecting nearly 125 million people globally, of whom around 20% experience moderate-to-severe symptoms, Taltz’s results could position it as a preferred treatment option, offering meaningful improvements in skin clearance and quality of life for patients.
As Taltz continues to outperform competing therapies, Lilly aims to enhance its immunology portfolio further, focusing on novel treatments for chronic autoimmune conditions. This trial solidifies Taltz’s role in the competitive plaque psoriasis market, where effective, durable solutions are in high demand.
References
